Ken Kengatharan
Managing General Partner @Atheneos Ventures
Signup · Get unlimited contacts
WORK HISTORY
Managing General Partner @Atheneos Ventures
Santa Clara (Silicon Valley), CA, US
EDUCATION
University of London
Post-Doctoral Fellowship, Cardiovascular Pharmacology
University of Leeds
BSc, Pharmacology
University of London
PhD, Pharmacology
Durham University
MBA (with Distinction), Specializing in Biotech Finance and Entrepreneurship
ABOUT KEN KENGATHARAN
A biopharma executive with extensive experience in successfully setting up, securing capital, and growing multiple companies. My major focus is to enable the translation of multiple innovative ideas around biology, tech, and engineering into solution-based transformative healthcare for patients. Interests: Orphan drugs & rare diseases (use of Tx, TxDx, digital Tx, functional medicine, medical devices, gene Tx >2.0), healthcare delivery, distributed ledger technology/blockchain [v1 to v(n>1)], AI/ML, hIoT, NFT tech, innovative ways to prepare + fund (incl. PIPE) high growth companies in healthcare: private/public (incl. SPACs) on NYSE/NASDAQ, HKEX, SGX, LSE. New pharma-biotech industry paradigm: Drug company -> Therapeutics management company (where a drug is part of a solution) New R&D paradigm: Common diseases (\"blockbusters\")-> “Orphanization” (via precision medicine)-> Orphan diseases (\"nichebusters\") Since 1998, experience: A. With a great team and supportive investors in each case, set up 7 companies (6 biotechs); now on 3+ cos + raised >$185MM in equity capital (mainly from blue-chip funds and biopharma). B. R&D: idea to Ph. 2/3: R&D & operations C. Corporate: BD & L (>$1Bn), corpdev, finance, pre-commercial D. Co-author of multiple articles and an invited presenter/panelist/moderator at biotech finance/R&D meetings incl. co-chairing international conferences on orphan drugs & rare diseases (I) Lecture series: “Freakonomics® of factors that determine the failure of a biotech company,” [Stanford (Aug, 2011), UCSF (Apr, 2012), London (Aug, 2012), Houston (Dec, 2013), Emory (Jan, 2019), SAGE (Nov, 2020)](II) Delivered: Cardiology Grand Rounds Feb. 6, 2014:\"Oral Anticoagulant Therapy in Patients with Prosthetic Heart Valve: Brief History, Challenges, and Future” (DeBakey Heart & Vascular Center, Houston Methodist, 2013 R&D Leadership Summit Interview discussing a new R&D investment risk-sharing model for pharma-biotech.[Conference Forum] Current: Board member at Auxesia Orion, Helios Orion, Renexxion Ireland, Apollorion Global, Radix Blend Co, and Advisor@Stanford’s SPARK program Past: BOD at Armetheon, EPi3, Athenagen, Altheos; Venture Advisor @Spire Bioventures; Visiting Scientist @Stanford, Advisory Board @Stanford\'s Cardinal Free Clinics, Mentor @UCSF (Entrepreneurship Prog.), Panelist@Stanford GSB\'s Ignite Program Experience: Start-up, translating ideas, investment+growth, Private Co to Public Co prep, M&A, licensing, business strategy, capital efficient R&D, product dev, IP, digital systems, executive coaching
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.